Nicht aus der Schweiz? Besuchen Sie lehmanns.de
Renal, Bladder, Prostate and Testicular Cancer -

Renal, Bladder, Prostate and Testicular Cancer

An Update, Second Edition
Buch | Hardcover
314 Seiten
2001 | 2nd New edition
CRC Press (Verlag)
978-1-84214-067-3 (ISBN)
CHF 129,95 inkl. MwSt
  • Titel ist leider vergriffen;
    keine Neuauflage
  • Artikel merken
A reference on the latest findings in the diagnosis, treatment, and prognosis of renal, bladder, prostate and testicular cancer. It contains 31 chapters by leading authorities dealing with the full range of clinical issues of importance in oncological urology in the early 21st century.
This cutting-edge clinical reference presents the latest findings and procedures concerning the diagnosis, treatment, management, and prognosis of renal, bladder, prostate and testicular cancer. Leading international authorities deal with the full range of clinical issues of paramount importance in oncological urology. They cover testicular cancer, renal cell and transitional cell carcinoma, new applications of cytokines, molecular markers, early diagnosis, characteristics of prostate cancer in different prostate-specific antigen ranges, the accuracy of biopsy information in determining outcome, laparoscopic radical prostatectomy, watchful waiting versus early endocrine treatment in "low risk" prostate cancer, biochemical outcome after radical prostatectomy, external beam radiation therapy or interstitial radiation therapy for clinically localized prostate cancer, screening for prostate cancer, chemo-endocrine prevention, the molecular mechanisms of hormone resistance in prostate cancer, early versus delayed endocrine therapy, antiandrogen monotherapy, intermittent androgen suppression, adjuvant and neoadjuvant treatment of prostate cancer, gene therapy in urology, non-endocrine systemic approaches for prostate cancer, novel detection strategies for transitional cell carcinoma, aminolevulinic acid induced fluorescence endoscopy (AFE) for detection of lower urinary tract tumors, Ta-T1 G1-2 transitional cell-carcinoma, BCG in transitional cell carcinoma, high-grade transitional cell carcinoma, brachytherapy for transitional cell carcinoma of the bladder, and systemic treatment in locally advanced and metastatic bladder cancer. Includes bibliographic references and index.

TESTICULAR AND RENAL CANCER. Testicular germ cell tumors, an update. Surgery for testicular cancer - indications, technique and results. Chemotherapy for testicular cancer. RENAL CARCINOMA. Prognostic factors and treatment decisions. Laparoscopic radical nephrectomy and nephroureterectomy for treatment of renal cell and transitional cell carcinoma. Modern management of advanced renal cell carcinoma. New applications of cytokines: inhalation of interleukin-2 to control pulmonary metastases. Management of advanced renal cell carcinoma. PROSTATE CANCER: EARLY DIAGNOSIS AND NATURAL HISTORY. Molecular markers (PSA, hK2, RT-PCR of PSA and hk2 mRNA). Early diagnosis. Characteristics of prostate cancer in different prostate-specific antigen ranges. How accurately does biopsy information determine outcome? Laparoscopic radical prostatectomy. MANAGEMENT OF LOCALIZED PROSTATE CANCER AND PREVENTATIVE APPROACHES. Watchful waiting or early endocrine treatment in 'low risk' prostate cancer. Biochemical outcome after radical prostatectomy, external beam radiation therapy or interstitial radiation therapy for clinically localized prostate cancer. Screening for prostate cancer - is mortality reduction already proven? Chemo-endocrine prevention. PROSTATE CANCER: ENDOCRINE TREATMENT. The molecular mechanisms of hormone resistance in prostate cancer. Early versus delayed endocrine therapy. Antiandrogen monotherapy - better quality of life? Metastatic prostate cancer - a randomized study of cyproterone acetate versus flutamide. Intermittent androgen suppression. PROSTATE CANCER: ADVANCED. Adjuvant and neoadjuvant treatment of prostate cancer. Gene therapy in urology. Non-endocrine systemic approaches for prostate cancer. BLADDER CANCER. Novel detection strategies for transitional cell carcinoma. Transurethral resection of bladder cancer controlled by 5-aminolevulinic acid-induced fluorescence endoscopy. Ta-T1 G1-G2 transitional cell carcinoma. BCG in transitional cell carcinoma - schedules of application, results and limitations. The approach to high-grade transitional cell carcinoma in Ta, CIS and T1 stages. Brachytherapy for transitional cell carcinoma of the bladder (category / T1 G3): an alternative to cystectomy? Current status of systemic treatment in locally advanced and metastatic bladder cancer. Index.

Zusatzinfo 53 Illustrations, black and white
Verlagsort London
Sprache englisch
Maße 190 x 254 mm
Gewicht 962 g
Themenwelt Medizinische Fachgebiete Innere Medizin Gastroenterologie
Medizin / Pharmazie Medizinische Fachgebiete Onkologie
Medizin / Pharmazie Medizinische Fachgebiete Urologie
ISBN-10 1-84214-067-1 / 1842140671
ISBN-13 978-1-84214-067-3 / 9781842140673
Zustand Neuware
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich